Bellevue Group AG Raises Stake in Encompass Health Co. (NYSE:EHC)

Bellevue Group AG lifted its position in shares of Encompass Health Co. (NYSE:EHC) by 25.9% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 14,980 shares of the company’s stock after buying an additional 3,080 shares during the quarter. Bellevue Group AG’s holdings in Encompass Health were worth $1,237,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. Principal Securities Inc. acquired a new stake in shares of Encompass Health in the fourth quarter worth approximately $25,000. Benjamin F. Edwards & Company Inc. lifted its position in Encompass Health by 360.2% during the fourth quarter. Benjamin F. Edwards & Company Inc. now owns 405 shares of the company’s stock valued at $27,000 after buying an additional 317 shares in the last quarter. McGlone Suttner Wealth Management Inc. purchased a new stake in shares of Encompass Health during the fourth quarter valued at approximately $30,000. GAMMA Investing LLC bought a new stake in shares of Encompass Health in the fourth quarter worth $33,000. Finally, Parallel Advisors LLC increased its stake in Encompass Health by 192.3% during the fourth quarter. Parallel Advisors LLC now owns 573 shares of the company’s stock valued at $38,000 after purchasing an additional 377 shares during the last quarter. 97.25% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

EHC has been the subject of a number of research analyst reports. Raymond James reissued a “strong-buy” rating and issued a $95.00 price target (up from $85.00) on shares of Encompass Health in a report on Friday, April 26th. Truist Financial upped their target price on Encompass Health from $95.00 to $100.00 and gave the company a “buy” rating in a report on Monday, July 15th. Royal Bank of Canada upped their target price on Encompass Health from $83.00 to $95.00 and gave the company an “outperform” rating in a research note on Wednesday, May 22nd. Leerink Partnrs upgraded Encompass Health to a “strong-buy” rating in a research note on Wednesday, July 10th. Finally, Mizuho increased their price objective on Encompass Health from $93.00 to $95.00 and gave the stock a “buy” rating in a research note on Thursday, April 25th. Nine investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Encompass Health presently has an average rating of “Buy” and a consensus target price of $96.50.

Encompass Health Trading Down 0.1 %

Shares of EHC traded down $0.06 during mid-day trading on Monday, reaching $91.55. 417,566 shares of the company were exchanged, compared to its average volume of 628,021. Encompass Health Co. has a 52 week low of $57.55 and a 52 week high of $92.45. The company has a debt-to-equity ratio of 1.14, a quick ratio of 1.37 and a current ratio of 1.37. The stock has a market capitalization of $9.22 billion, a PE ratio of 24.76, a PEG ratio of 1.43 and a beta of 0.89. The business has a 50 day simple moving average of $85.59 and a two-hundred day simple moving average of $80.30.

Encompass Health Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, October 15th. Stockholders of record on Tuesday, October 1st will be given a $0.17 dividend. The ex-dividend date of this dividend is Tuesday, October 1st. This is a boost from Encompass Health’s previous quarterly dividend of $0.15. This represents a $0.68 annualized dividend and a dividend yield of 0.74%. Encompass Health’s payout ratio is 16.22%.

Insider Activity

In other news, CEO Mark J. Tarr sold 44,976 shares of the company’s stock in a transaction dated Tuesday, April 30th. The stock was sold at an average price of $83.27, for a total value of $3,745,151.52. Following the completion of the transaction, the chief executive officer now directly owns 554,098 shares in the company, valued at approximately $46,139,740.46. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other news, Director Greg D. Carmichael bought 2,000 shares of Encompass Health stock in a transaction on Friday, May 3rd. The shares were purchased at an average price of $83.73 per share, for a total transaction of $167,460.00. Following the acquisition, the director now owns 17,050 shares of the company’s stock, valued at $1,427,596.50. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Mark J. Tarr sold 44,976 shares of the company’s stock in a transaction that occurred on Tuesday, April 30th. The stock was sold at an average price of $83.27, for a total value of $3,745,151.52. Following the completion of the sale, the chief executive officer now owns 554,098 shares in the company, valued at approximately $46,139,740.46. The disclosure for this sale can be found here. Over the last three months, insiders sold 69,519 shares of company stock worth $5,816,091. 2.10% of the stock is owned by corporate insiders.

Encompass Health Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.